Cancer journal impact factor 1 ??????

The Journal Citation Reports by Thomson Reuters for the year 2012 is available now. The list is being embedded here as an excel file which can be downloaded and viewed on full screen by choosing the options below. Carboplatin dosing based on renal function has been shown to result in more reproducible and reliable drug exposures than dosing based on surface area in children (Thomas et al, 2000).
This data set from 337 GFR tests was used to estimate the difference in carboplatin dose that would be seen after implementation of the new regulations in individual centres.
Brandt JR, Wong CS, Hanrahan JD, Qualls C, McAfee N, Watkins SL (2006) Estimating absolute glomerular filtration rate in children. From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. This journal is a member of and subscribes to the principles of the Committee on Publication Ethics. CellMark Biopharma, a global innovator in medical nutrition combining scientifically based medical research with innovative multi-platform technology congratulates Erica Boliek on her appointment to the European Society of Clinical Nutrition and Metabolism official journal, Clinical Nutrition. European and United States share a common, yet highly disturbing cancer statistic: 20-40% of cancer patients die from malnutrition and not the cancer itself. The European Society of Clinical Nutrition and Metabolism official journal is Clinical Nutrition with an impact factor 3.41, making it #12 among the 59 journals of Nutrition and Dietetics.
CellMark Biopharma congratulates Erica Boliek and is proud to have her as part of the management team at the company fostering a better today and future for everyone. INDUSTRY KEYWORDS: Biotechnology, Cancer, cancer super drink, Clinical Trials, Daniel Von Hoff, Stand Up To Cancer, Oncology, Pharmaceutical, Research, Health, CellMark Biopharma, Derek Vest, Kalos Therapeutics, Erica Boliek, Dr.
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Emergent BioSolutions, Inc.
IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Lipocine Inc. INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Juno Therapeutics Inc.
It is important that accurate assessments of renal function are carried out consistently across clinical centres, a view supported by recently published British Nuclear Medicine Society (BNMS) guidelines for measuring glomerular filtration rate (GFR).
This approach not only minimises the risk of underdosing and hence inadequate treatment, but also reduces overdosing, which may be associated with the risk of increased toxicity.
The findings indicated that at the time the survey was carried out all centres followed the BNMS guidelines with respect to the use of a radioisotopic method to measure GFR, with 19 of 21 centres using 51Cr-EDTA and the remaining two centres using 99mTc-DTPA. CellMark has taken yet another step in reaching its highly ambitious goal of cutting those deaths in half through its Medical Nutrition line as well as its ever increasing presence and influence in the international nutrition world.
It is an international journal providing essential scientific information on nutritional and metabolic care and the relationship between nutrition and disease both in the setting of basic science and clinical practice. These guidelines recommend the use of a radioisotope method for GFR determination, with between two and five blood samples taken starting 2 h after radioisotope injection and application of the Brochner-Mortensen (BM) correction factor. As renal function-based carboplatin dosing is now used routinely in clinical practice in many multicentre protocols, it is important that accurate assessments of renal function in children are carried out consistently across paediatric oncology clinical centres.Glomerular filtration rate (GFR) estimation is widely used as a standard measure of renal function in both children and adults. The Newell formula based on patient weight and 51Cr-EDTA t1/2, equation (1), was used to estimate the carboplatin dose to assess the impact of changing sampling times.
Either the central or peripheral route was used to inject the radioisotope tracer in two-thirds of centres, depending on whether the patient had a single or a double-lumen central venous line, whereas the remaining third used the peripheral route only.
CellMark Biopharma proudly announced that Erica Boliek, Chief of Research and Development, has been added to the editorial board as a reviewer for The European Society for Clinical Nutrition and Metabolism Journal of Clinical Nutrition.

Among her other credentials are Board Certified Athletic Trainer, CPCC (certified professional cancer coach) and manuscript reviewer and editor for the Journal of Athletic Training and the American College of Sports Medicine. To study the likely impact of these guidelines, we have investigated current practices of measuring GFR in all 21 Children's Cancer and Leukaemia Group (CCLG) paediatric oncology centres in the United Kingdom. The BNMS recommendations indicate the use of one lumen of a double-lumen central venous line to inject the radioisotope and the second for blood sampling wherever possible. Boliek, will be a part of the peer-reviewing process that subjects scientific research papers to revision based on the scientific merit and validity of the article and its methodology before being published. She has published works in the Journal of American Academy of Physician Assistants and lectured globally. This information was used to evaluate the potential impact on renal function-based carboplatin dosing using raw 51Cr-EDTA clearance data from 337 GFR tests carried out in children with cancer. Use of exogenous markers for estimating GFR involves administration of the marker as either a bolus injection or an infusion and measurement of concentrations in serial blood and/or urine samples over a period of time. The alternative Newell formula based on uncorrected GFR and patient weight (modified Calvert formula), equation (2), was used to estimate the carboplatin dose when centres implemented a change in the correction factor used (Newell et al, 1993). Consequently, this would lead to a decrease in the dose of carboplatin calculated using the Newell formula on the basis of uncorrected GFR and weight.
The radioisotope tracers 51Cr-EDTA and 99Tc-DTPA have found widespread use in paediatric oncology and they are now accepted as a simple, safe and accurate way of measuring GFR. A greater proportion of patients would have an alteration in carboplatin dose when centres not using any correction factor implement the BM correction. In the United Kingdom, it is standard practice in the majority of Children's Cancer and Leukaemia Group (CCLG) centres to estimate GFR using 51Cr-EDTA, whereas in the United States, 99Tc-DTPA is the radioisotope tracer of choice (Fleming et al, 2004).Estimation of GFR from the clearance of radiolabelled tracer is most accurate if multiple blood samples are taken after administration as the decrease in plasma concentration of the tracer is often biexponential, with a rapid early phase and a later slower phase (Piciotto et al, 1992). Although creatinine clearance is a reliable marker in day-to-day practice in adults, its use in paediatrics has been questioned and there are situations where a more accurate measure of GFR is preferred (Finney et al, 2000; Holweger et al, 2005).
However, for routine clinical practice, sampling is usually restricted to the second phase of the clearance, with the slope–intercept method commonly used for the determination of GFR.
This information may be particularly important in clinical situations where potentially nephrotoxic drugs are administered, in addition to allowing for accurate renal function-based dosing of anticancer drugs such as carboplatin (Calvert et al, 1989; Holweger et al, 2005). This study highlights current variations in renal function measurement between clinical centres and the potential impact on carboplatin dosing. As the more rapid early phase of the clearance is not accounted for when using this method, it is necessary to correct for systematic errors introduced into the derived GFR values. It has been well established that the use of radioisotope tracers, such as 51Cr-EDTA and 99mTc-DTPA, are reliable methods for the accurate estimation of GFR (Rehling et al, 1984; Fawdry et al, 1985). The most popular methods used to correct for these errors are known as the Chantler and Brochner-Mortensen (BM) corrections (Brochner-Mortensen, 1972; Chantler and Barratt, 1972). Techniques of limited sampling restricted to the slow exponential phase of radioisotope clearance provide a reasonable compromise to avoid the complexity of measuring GFR using the biexponential method where multiple blood samples need to be taken at earlier time points.
Whereas the former uses a constant multiplicative correction factor to adjust the GFR values obtained, the latter uses a quadratic correction and is dependent on the individual's body surface area.In 2004, the British Nuclear Medicine Society (BNMS) published guidelines to assist nuclear medicine specialists in performing GFR studies and interpreting and reporting the results obtained (Fleming et al, 2004).
This is particularly important in paediatric practice where blood sampling can be a traumatic experience to a child and where blood volumes need to be minimised. On the basis of the above findings from the questionnaire survey, implementation of these guidelines would result in the omission of data obtained from early blood samples taken within 2 h of radioisotope administration in six centres. Therefore, to study the likely impact of the BNMS recommendations, a questionnaire survey concerning the current practices of estimating GFR in children was sent to all CCLG paediatric oncology centres in the United Kingdom.

In addition, 12 centres would shift from either applying no correction, or using the Chantler correction, to implement the BM correction. In view of the BNMS recommendations, it was prudent to investigate the potential effects of changes in methodologies for determining GFR on carboplatin dosing in children with cancer. The questionnaire was sent to centres in May 2006 and all replies were returned by October 2006. The questionnaire was completed by a paediatric oncology consultant or paediatric oncology research nurse in conjunction with the local medical physicist at each centre.
The survey requested detailed information regarding the methodology currently practiced in estimating GFR in paediatric oncology patients. The vast majority of patients would have a decrease in the dose of carboplatin administered following the omission of the early blood sample, as illustrated in Figure 1A.
The questionnaire also collected details on the existing practice of estimating carboplatin dose based on patient renal function in children with cancer. A follow-up survey was carried out in February 2008 to establish whether any changes had been made to centre practices since the completion of the original questionnaire.Impact of BNMS recommendations on carboplatin dosingRetrospective data from 337 GFR tests carried out on a total of 178 children in Newcastle upon Tyne were used to study the impact of the new BNMS recommendations on carboplatin dosing.
Omitting the 1-h blood sample after injection of the radioisotope increased the estimate of 51Cr-EDTA half-life and consequently decreased the dose of carboplatin estimated using 51Cr-EDTA half-life and weight. The raw data used for this analysis were from tests conducted in children with blood samples taken at 1, 2, 3 and 4 h after injection of 51Cr-EDTA and covered a wide range of GFR values. Also, the 10% change of carboplatin dose used for our analysis represents an arbitrary cutoff point.
This involved fitting the data from the 2, 3 and 4 h samples to a single exponential equation by taking the natural logarithm of the plasma concentrations and use of linear regression analysis against time to determine the slope and intercept at time zero for the exponential. As the predominant shift is towards a decrease in carboplatin dose, implementation of the BNMS recommendations should not raise any concerns regarding potential increases in drug toxicity but an impact on efficacy cannot be ruled out.These findings highlight the potential problem that patients with similar physical characteristics and renal function could receive different carboplatin doses at different centres on the basis of the methodology used to estimate GFR or 51Cr-EDTA half-life. Indeed, it is not unlikely for such an occurrence to be observed in patients being treated on the same clinical protocol. As many paediatric oncology patients in the United Kingdom are recruited to national and international trials, it is logical that the methodology of estimating GFR and carboplatin dose estimation should be standardized, so that the outcome data for these trials are not confounded by this factor.
This task could arguably be made more straightforward if the Newell formula was universally used for the determination of renal function-based carboplatin dosing in children, as the 51Cr-EDTA half-life on which it is based is only dependent on the radioisotope sampling times and does not depend on the choice of correction factor. Implementation of a change in the type of slope–intercept correction method used for determining GFR, in addition to the changes in sampling times, would impact on the majority of CCLG centres (16 of 21) and there may be some reluctance to implement such changes. Despite the publication of the BNMS recommendations in 2004, there remains substantial variation in practice in paediatric oncology centres across the United Kindom. Indeed, in a follow-up survey carried out as part of this study in February 2008, only three centres reported a change to the previously used method of GFR determination.
While one centre had adopted the BNMS recommendations during this time interval, changes in the additional two centres related to the inclusion of a third 51Cr-EDTA sampling time point and a shift from the use of 51Cr-EDTA to iohexol as the radioisotopic tracer, respectively. The standardised use of 51Cr-EDTA half-life as the renal parameter to estimate carboplatin dose would prevent such problems occurring.In summary, our findings suggest that steps should be taken to implement the new BNMS guidelines and standardise methodologies of GFR estimation and renal function-based carboplatin dose calculation in all centres.

Natural cure for bone cancer jaw
Gastritis treatment alternative medicine
Natural treatment for lung cancer stage 4
Homemade alopecia treatment

Comments to «Cancer journal impact factor 1 ??????»

  1. FiDaN writes:
    Podría reaccionar, y los diferentes tipos de tratamiento que podrían funcionar friend acquired pregnant just for liver.
  2. nedved_42 writes:
    Not less than six treatment periods is usually a beneficial possibility for circulate from the palms.